Mainstream

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model

Post ContentrprxRead More

You might also be interested in reading Elon Musk’s SEC Feud Sparks Outrage: Ripple, Ramaswamy, Palihapitiya Slam Corrupt Tactics.

August 6, 2025
In Mainstream